8月19日，黄山胶囊今日收盘8.06元，上涨1.51%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到45.69倍，总市值24.11亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均59.49倍，行业中值40.19倍，黄山胶囊排 名第82位。 股东方面，截至2025年3月31日，黄山胶囊股东户数18378户，较上次减少26户，户均持股市值35.28万 元，户均持股数量2.76万股。 安徽黄山胶囊股份有限公司的主营业务是明胶空心胶囊和肠溶明胶空心胶囊的研发、生产与销售。公司 的主要产品是明胶空心胶囊、肠溶明胶空心胶囊、羟丙甲纤维素空心胶囊、普鲁兰多糖空心胶囊。公司 是中国最早的药用空心胶囊生产企业之一，拥有三十多年高品质药用空心胶囊生产历史。在药用空心胶 囊行业，公司具有较高的知名度，现为中国医药包装协会突出贡献奖成员单位、药用空心胶囊专业委员 会副主任单位之一。公司的商标被评为安徽省著名商标，"旌川"牌药用空心胶囊获"安徽名牌产品"称 号。"旌川"牌明胶空心胶囊和肠溶明胶空心胶囊荣获"中国化学制药行业药用辅料优秀产品品牌"。 最新一期业绩显示，2025年一季报，公司实现营业收入1.1 ...

Core Insights - The report highlights the importance of CFOs in listed companies, with the total salary scale for CFOs in A-share companies reaching 4.27 billion yuan in 2024 [1] - The average annual salary for CFOs in the raw material pharmaceutical sector is 661,200 yuan [1] Salary Distribution - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical with 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical with 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical with 1.57 million yuan [1] - The salary distribution shows that 44% of CFOs earn below 500,000 yuan, 44% earn between 500,000 and 1 million yuan, and 12% earn above 1 million yuan [1] Age and Education Distribution - CFOs aged 40-50 constitute the majority at 36%, while those aged 60 and above account for 5% [1] - The educational background of CFOs shows that 65% hold a bachelor's degree, 21% have a master's degree, and only 2% have a high school diploma [1] Salary Changes - Liu Qingke from Huangshan Capsule experienced the largest salary decrease at 19.04%, while Qian Dan from Nengte Technology saw the highest salary increase at 100.58% [1]

从薪酬分布看，A股原料药公司CFO年薪平均值为66.12万元。经统计，处于50万以下、50万-100万、 100万以上各区间的人数占比分别为44%、44%、12%。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到36%；60岁以上的CFO占比 为5%；50岁-60岁的CFO群体占比为33%；40岁及以下CFO群体占比为26%。其中，目前仍任职的最年 轻的上市公司CFO年龄33岁，为新诺威的戴龙。 从CFO的学历分布看，拥有高中、大专、本科、硕士学历的CFO占比分别为2%、12%、65%、21%。其 中，以高中学历出任CFO的仅1人，为海森药业的潘爱娟。 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有43家上市原料药公司，其 聘任总体情况如下（部分统计 ...

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 708,000 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [2] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [2] - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.17 million yuan, and 1.1 million yuan respectively [2] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [1] - More than half of the company secretaries hold a bachelor's degree, with 9% having an associate degree, 52% a bachelor's degree, and 39% a master's degree [1] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [2] - The top five companies with the most investor meetings conducted 520, 437, 325, 323, and 291 meetings respectively [3]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for secretaries in the A-share pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] - The top five highest-paid secretaries have salaries ranging from 1.0832 million to 1.9309 million yuan, with varying years of service [7] Age and Education Demographics - The majority of company secretaries (60%) are aged between 30 and 50 years, while 38% are over 50 years, and only 2% are 30 years or younger [1] - More than half (52%) of the secretaries hold a bachelor's degree, with 39% holding a master's degree and 9% holding an associate degree [3] Investor Relations - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - The five companies with the highest number of investor meetings range from 291 to 520 meetings per year, with their secretaries' salaries varying widely [9]

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [3] - Over half of the company secretaries hold a bachelor's degree, with the breakdown being 9% with an associate degree, 52% with a bachelor's degree, and 39% with a master's degree [3] Top and Bottom Salaries - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.176 million yuan, and 1.0832 million yuan, respectively [7] - The three lowest-paid company secretaries earn 174,200 yuan, 187,500 yuan, and 190,700 yuan, all of whom have served in their positions for less than two years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - Five companies reported zero investor meetings, while the top five companies for investor engagement had between 291 and 520 meetings, with corresponding secretary salaries ranging from 267,000 yuan to 444,200 yuan [9]

Company Overview - Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, with over 30 years of high-quality production history [1] - The company is one of the earliest manufacturers of pharmaceutical hollow capsules in China and has a high reputation in the industry [1] Financial Performance - For Q1 2025, the company reported operating revenue of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, up 22.90% year-on-year [2] - The sales gross margin for the same period was 29.26% [2] Market Position - The company's current price-to-earnings (PE) ratio is 44.84, compared to the industry average of 54.89 and the industry median of 37.06 [2] - Huangshan Capsule's total market capitalization is 2.366 billion yuan [1] Industry Context - The medical device industry, where Huangshan Capsule operates, has an average PE ratio of 54.89 and a median of 37.06 [2] - Huangshan Capsule ranks 83rd in terms of PE ratio within its industry [1] Capital Flow - On July 31, the company experienced a net outflow of main funds amounting to 2.725 million yuan, with a total outflow of 3.7357 million yuan over the past five days [1]

Company Overview - Huangshan Capsule Co., Ltd. specializes in the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, being one of the earliest manufacturers in China with over 30 years of high-quality production history [1][2] - The company has a strong reputation in the pharmaceutical hollow capsule industry and is a member of the China Pharmaceutical Packaging Association, recognized for its contributions [1] Financial Performance - For Q1 2025, the company reported revenue of 119 million yuan, a year-on-year increase of 0.53%, and a net profit of 18.837 million yuan, reflecting a year-on-year growth of 22.90% [2] - The sales gross margin for the same period was 29.26% [2] Market Position - As of July 16, the company's stock closed at 7.76 yuan, with a PE ratio of 43.99, marking a new low in 353 days, and a total market capitalization of 2.321 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 51.87, with a median of 37.48, placing Huangshan Capsule at the 84th position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders for Huangshan Capsule was 18,378, a decrease of 26 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Group 1 - *ST San Sheng (002742.SZ): The controlling shareholder Pan Xianwen's judicial auction of 32.2 million shares has been completed, with 30 million shares transferred, accounting for 6.94% of the total share capital. After the reduction, Pan Xianwen's shareholding ratio decreased from 24.20% to 17.26%, which will not lead to a change in company control [1] - Aike Co., Ltd. (300889.SZ): Shareholder Zhang Fengbin, holding over 5%, reduced his stake by 1% (1.67818 million shares) from May 13 to June 27, 2025, bringing his holding to 7.9902% [1] - Anlu Technology (688107.SH): The shareholder National Integrated Circuit Industry Investment Fund Co., Ltd. completed its reduction plan, selling 4.008493 million shares (1% of total share capital) from May 8 to June 30, 2025, with a total reduction amount of 109.36 million yuan, current holding ratio at 5.76% [1] Group 2 - Anshuo Information (300380.SZ): The controlling shareholder Shanghai Anshuo Technology Development Co., Ltd. and actual controllers reduced their stakes by 1.16% (1.599416 million shares), 0.94% (1.300187 million shares), and 0.65% (900,000 shares) respectively [1] - Baoming Technology (002992.SZ): Directors and management plan to reduce their holdings by a total of 0.0107%, 0.0714%, and 0.0107% over the next three months [2] - Beiyikang (870199.BJ): Employee shareholding platforms completed their reduction plans, selling 546,284 shares (0.8%) and 131,650 shares (0.19%) [2] Group 3 - Boyun New Materials (002297.SZ): Major shareholder Hunan Xiangtou High-tech Venture Capital Co., Ltd. reduced its stake by 406.74 million shares (0.71%) from June 5 to June 30, 2025, bringing its holding to 6.99% [2] - Dongwei Technology (688700.SH): Specific shareholder Xie Yulong completed a reduction plan, selling 574,857 shares (0.1927%) from June 4 to June 30, 2025, with a total reduction amount of 21.362156 million yuan, current holding ratio at 0% [2] - Fuzhi Environmental Protection (688335.SH): Major shareholder Deqing Junjie Enterprise Management Partnership plans to reduce up to 4.441035 million shares (3%) over the next three months [3] Group 4 - Gu Gao Technology (301510.SZ): Shareholder Beijing Equity Investment Development Management Center completed its reduction plan, selling 4.0001 million shares (1%) from June 5 to June 30, 2025, bringing its holding to 7.68% [3] - Guangbo Co., Ltd. (002103.SZ): Shareholder Ren Hangzhong reduced his stake by 156,440 shares (0.2928%), bringing his holding to 9.99999% [3] - Guoke Military Industry (688543.SH): Specific shareholders Yang Minghua and Chen Gonglin plan to reduce up to 2.08842 million shares (1%) and 3.789115 million shares (1.8143%) over the next three months [3] Group 5 - Guorui Technology (300600.SZ): Major shareholder Gong Ruiliang reduced his stake by 3.243209 million shares (1.1%) from June 27 to July 1, 2025, bringing his holding to 20.63% [4] - Hangzhou Thermal Power (605011.SH): Shareholder Huashi Investment plans to reduce up to 5.997 million shares (1.4989%) over the next three months [4] - Huaya Intelligent (003043.SZ): Executives plan to reduce their holdings by a total of 0.0132%, 0.0092%, and 0.0092% over the next three months [4]

Core Viewpoint - The announcement details the completion of a share reduction plan by senior executive Ye Songlin of Anhui Huangshan Capsule Co., Ltd., involving the sale of 430,000 shares, which represents 0.1438% of the company's total share capital [1]. Group 1: Share Reduction Details - Ye Songlin executed the share reduction through centralized bidding from June 24, 2025, to June 30, 2025, at an average price of 7.3785 yuan per share [1]. - The total number of shares held by Ye Songlin before the reduction was 1,725,500, which decreased to 1,295,500 after the reduction [1]. - The shares sold were originally held prior to the company's initial public offering and included shares from capital reserves, with the selling price ranging from 7.37 yuan to 7.40 yuan per share [1]. Group 2: Compliance and Regulations - The share reduction complies with relevant regulations, including the stock exchange listing rules and management rules for shares held by directors and senior management [1]. - Ye Songlin has adhered to previously disclosed commitments regarding shareholding intentions and has not violated any disclosed reduction plans [1]. - The reduction of shares will not lead to a change in company control or significantly impact the company's governance structure and ongoing operations [1].